25th week of 2014 patent applcation highlights part 49 |
Patent application number | Title | Published |
20140170055 | POLYCRYSTALLINE DIAMOND AND MANUFACTURING METHOD THEREOF - Nano polycrystalline diamond is composed of carbon and a plurality of impurities other than carbon. A concentration of each of the plurality of impurities is not higher than 0.01 mass %, and the nano polycrystalline diamond has a crystal grain size (a maximum length) not greater than 500 nm. The nano polycrystalline diamond can be fabricated by preparing graphite in which a concentration of an impurity is not higher than 0.01 mass % and converting graphite to diamond by applying an ultra-high pressure and a high temperature to graphite. | 2014-06-19 |
20140170056 | METHOD FOR MAKING CARBON NANOTUBES - A method for making carbon nanotubes is disclosed. The method includes steps of: (a) providing a growing device, wherein the growing device comprises a reacting room having a gas inlet and a gas outlet; (b) forming a catalyst layer on a first planar surface of a growing substrate; (c) placing the growing substrate and a receiving substrate having a second planar surface in the reacting room, wherein the first planar surface and the second planar surface are parallel with each other; (d) introducing a carbonaceous gas in the reaction room to form a gas flow and growing a first plurality of carbon nanotubes from the growing substrate, wherein the first plurality of carbon nanotubes are brought above the receiving substrate by the gas flow; and (e) stopping the introducing the carbonaceous gas such that the first plurality of carbon nanotubes deposits on the receiving substrate. | 2014-06-19 |
20140170057 | METHOD AND APPARATUS FOR MANUFACTURING GRAPHENE SHEET - Disclosed is an apparatus for manufacturing graphene sheets. The apparatus includes a gas tube, and a hydrocarbon gas source connected to a front part of the gas tube for providing a hydrocarbon gas through the gas tube. The apparatus also includes a microwave generator to generate a microwave passing a middle part of the gas tube through a waveguide tube to form a microwave plasma torch from the hydrocarbon gas, wherein the hydrocarbon gas is cracked by the microwave plasma torch to form graphene sheets. The apparatus includes a tube collector connected to a back part of the gas tube for collecting the graphene sheets. | 2014-06-19 |
20140170058 | PROCESS FOR THE REMOVAL OF PALLADIUM FROM 4-AMINO-3-HALO-5-FLUORO-6-(ARYL) PYRIDINE-2-CARBOXYLATES AND 4-AMINO-3-HALO-6-(ARYL)PYRIDINE-2-CARBOXYLATES - Residual palladium is removed and recovered from 4-amino-3-halo-5-fluoro-6-(aryl)pyridine-2-carboxylates and 4-amino-3-halo-6-(aryl)pyridine-2-carboxylates by treatment with an aqueous solution containing from about 20 to about 50% of an alkali metal bisulfite at a temperature from about 60 to about 90° C. and a pH from about 3.8 to about 7.0. | 2014-06-19 |
20140170059 | ELECTRODIAPHRAGMALYSIS - Electrochemically-treated water having an electron deficiency is described, which may be attained by a process comprising the following steps: | 2014-06-19 |
20140170060 | ENVIRONMENTALLY RESPONSIBLE APPROACHES TO SYNTHESIS OF MULTI-FUNCTIONAL FERRATE - People are increasingly interested in use of potassium ferrate [K | 2014-06-19 |
20140170061 | STAGED MEMBRANE PROCESS FOR HIGH PRESSURE HYDROGEN PRODUCTION - “A hydrogen purification process is provided. This process includes separating hydrogen from a hydrogen containing stream in at least two sequential palladium membrane purification zones, wherein each purification zone has a permeate side, wherein the permeate side pressure of purification zones are not the same.” | 2014-06-19 |
20140170062 | LOW SILICON SAPO-42 AND METHOD OF MAKING - A porous crystalline silico-alumino-phosphate molecular sieve is described. The molecular sieve has a framework composition on an anhydrous and calcined basis expressed by an empirical formula | 2014-06-19 |
20140170063 | Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity - The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 ROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. | 2014-06-19 |
20140170064 | METHODS AND COMPOSITIONS FOR RADIOHALOGEN PROTEIN LABELING - Methods and compositions are provided for labeling proteins with radiohalogen-label reagents. Radiohalogen-labeled proteins may be used for imaging studies, as therapeutics and in diagnostic tests. The [ | 2014-06-19 |
20140170065 | Methods and Compositions for Treatment of Human Immunodeficiency Virus Infection with Conjugated Antibodies or Antibody Fragments - The present invention concerns methods and compositions for treatment of HIV infection in a subject. The compositions may comprise a targeting molecule against an HIV antigen, such as an anti-HIV antibody or antibody fragment. The anti-HIV antibody or fragment may be conjugated to a variety of cytotoxic agents, such as doxorubicin. In a preferred embodiment, the antibody or fragment is P4/D10. Other embodiments may concern methods of imaging, detection or diagnosis of HIV infection in a subject using an anti-HIV antibody or fragment conjugated to a diagnostic agent. In alternative embodiments, a bispecific antibody with at least one binding site for an HIV antigen and at least one binding site for a carrier molecule may be administered, optionally followed by a clearing agent, followed by administration of a carrier molecule conjugated to a therapeutic agent. | 2014-06-19 |
20140170066 | INTEGRIN TARGETING AGENTS AND IN-VIVO AND IN-VITRO IMAGING METHODS USING THE SAME - The invention provides a family of agents that target integrins, which can be used as imaging agents and/or therapeutic agents. The agents can be used to image angiogenesis, inflammation or other physiological processes in a subject. | 2014-06-19 |
20140170067 | NEW LIGANDS FOR TARGETING OF S1P RECEPTORS FOR IN VIVO IMAGING AND TREATMENT OF DISEASES - The present invention relates to novel compounds of formulae (I) and (II) which are useful in the prevention, treatment and diagnosis, in vivo diagnosis of diseases or disorders related to S1P receptors, in particular, in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases. | 2014-06-19 |
20140170068 | BIOMARKER FOR CORONARY ARTERY DISEASE - In various embodiments methods are provided for identifying a mammal having an elevated risk for an adverse cardiac event (e.g. an MI) and/or determining the prognosis for the mammal. In certain embodiments the methods comprise determining, or causing to be determined, the presence and/or level of antibodies that bind a malondialdehyde-acetaldehyde adduct (MAA adduct) in a biological sample from the mammal, where an elevated level of anti-MAA adduct antibodies, as compared to the level found in a normal healthy mammal is an indicator that that said mammal has one or more atherosclerotic lesions and/or is at elevated risk for a myocardial infarction. | 2014-06-19 |
20140170069 | ASSESSMENT OF CORONARY HEART DISEASE WITH CARBON DIOXIDE - The invention provides methods for diagnosing coronary heart disease in a subject in need thereof comprising administering an admixture comprising CO | 2014-06-19 |
20140170070 | STABLE COLLOIDAL GOLD NANOPARTICLES WITH CONTROLLABLE SURFACE MODIFICATION AND FUNCTIONALIZATION - In the present invention, a method of producing stable bare colloidal gold nanoparticles is disclosed. The nanoparticles can subsequently be subjected to partial or full surface modification. The method comprises preparation of colloidal gold nanoparticles in a liquid by employing a top-down nanofabrication method using bulk gold as a source material. The surface modification of these nanoparticles is carried out by adding one or multiple types of ligands each containing functional groups which exhibit affinity for gold nanoparticle surfaces to produce the conjugates. Because of the high efficiency and excellent stability of the nanoparticles produced by this method, the fabricated gold nanoparticle conjugates can have surface coverage with functional ligands which can be tuned to be any percent value between 0 and 100%. | 2014-06-19 |
20140170071 | Modified Pyrazine Derivatives and Uses Thereof - In some embodiments, the invention provides modified pyrazine derivatives containing a central pyrazine ring with two secondary amine groups attached directly to the central pyrazine ring and two amino carbonyl groups attached directly to the central pyrazine ring. The secondary amine groups are terminated by alkyl groups containing from 1 to 6 carbons. The amino carbonyl groups can be terminated by a wide range of substituents including, but not limited to, alkyl and alkylene groups, polyether groups, including poly(ethylene glycol) groups, secondary and tertiary amine groups, polyhydroxylated alkyl groups, amino carbonyl groups, amino thioketone groups, and combinations thereof. In some embodiments, the invention provides modified pyrazine derivatives useful as optical agents in a wide variety of biomedical imaging procedures, including diagnostic and imaging procedures. In an embodiment, for example, modified pyrazine derivatives are provided which are useful in monitoring organ and system functioning, for example in monitoring renal system functioning. | 2014-06-19 |
20140170072 | THERAPEUTIC METHODS AND COMPOSITIONS FOR SOLID DELIVERY - An administration device comprising an array of needles, one or more fluid agents, and at least one hydrogel is described. The device can simultaneously deliver a plurality of fluid agents along respective axes into a tissue. The use of hydrogel leads to constrained delivery of the fluid agents. The constrained delivery of an agent is also achieved by depositing a drug implant into a tissue. The effect of an agent on the tissue can be evaluated thereafter. In addition, the invention is directed to treating muscle diseases by delivering a therapeutic agent in vivo, and the use of reporter tissues for candidate drug evaluation, detecting and characterizing resistance. | 2014-06-19 |
20140170073 | NANOPARTICULATE PROBE FOR IN VIVO MONITORING OF TISSUE OXYGENATION - A new class of micro- and nano-particulate paramagnetic spin probes especially useful for magnetic resonance imaging techniques, including electron paramagnetic resonance (EPR) and magnetic resonance imaging (MRI). The probes are lithium phthalocyanine derivative compounds. Also provided are suspensions and emulsions comprising lithium phthalocyanine derivative probes. Also provided are noninvasive methods for measuring noninvasive methods of measuring oxygen concentration, oxygen partial pressure, oxygen metabolism, and nitric oxide concentration in a specific tissue, organ, or cell in vivo or in vitro. | 2014-06-19 |
20140170074 | SAFETY MATERIAL AND SYSTEM - Compositions and methods for deterring and/or visually identifying oral contact with objects that are hazardous upon oral contact or ingestion are disclosed. The compositions generally comprise a colourant and a carrier and may further comprise an aversive agent, a salivating agent, and/or an emetic. The compositions may be particularly useful for application to batteries, including button cells. | 2014-06-19 |
20140170075 | NON-INVASIVE IMAGING METHODS FOR PATIENT SELECTION FOR TREATMENT WITH NANOPARTICULATE THERAPEUTIC AGENTS - Methods for providing treatment of pathologic conditions with nanoparticulate therapeutic agents are disclosed. Novel methods for determining liposomal deposition at sites of pathology using non-invasive imaging are also disclosed. | 2014-06-19 |
20140170076 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES - A composition comprises an anti-nucleolin agent conjugated to nanoparticles. The nanoparticles are non-magnetic, not iron oxide and not polyacrylamide. Furthermore, a pharmaceutical composition for treating cancer comprises a composition including an anti-nucleolin agent conjugated to nanoparticles, and a pharmaceutically acceptable carrier. | 2014-06-19 |
20140170077 | HIGH-SENSITIVITY MAGNETIC RESONANCE IMAGING NANO-CONTRAST AGENT BASED ON AN ANIONIC POLYMER AND CATIONIC POLYMER ION COMPLEX, AND A PRODUCTION METHOD THEREFOR - The present invention relates to a nano-composite containing anionic and cationic polymers and a method for preparing thereof, and more particularly to a poly-gamma-glutamic acid (γ-PGA)/chitosan/manganese iron oxide nanoparticle composite prepared by encapsulating iron oxide-based nanoparticles in a γ-PGA/chitosan polymer composite using the ionic self-assembly properties of poly-gamma-glutamic acid (γ-PGA) and chitosan, which are biocompatible polymer materials, and to a method for preparing thereof. | 2014-06-19 |
20140170078 | MAGNETIC RESONANCE IMAGING T2 CONTRAST MEDIUM FOR CELL CONTRASTING, AND METHOD FOR MANUFACTURING SAME - The invention relates to a magnetic resonance imaging T | 2014-06-19 |
20140170079 | ABUSE-PROOFED DOSAGE FORM - The invention relates to a dosage form that is thermoformed without discoloration and is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse. The invention also relates to a corresponding method for producing said dosage form. | 2014-06-19 |
20140170080 | ANTIOXIDANT TOPICAL COMPOSITIONS - The present invention relates to topical aerosol compositions comprising L-ascorbic acid. The compositions comprise (a) L-ascorbic acid, or a pharmaceutically acceptable salt or ester thereof, (b) water, (c) lower alcohol and (d) an aerosol propellant. In particular embodiments of the invention, the formulations are actuated as an aerosol spray or aerosol foam. The formulations are suitable for minimizing aging of the skin. | 2014-06-19 |
20140170081 | PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATION - The inventive subject matter relates to a pharmaceutical aerosol product suitable for administration by oral or nasal inhalation and its use in the treatment of respiratory diseases, in particular in the treatment of children. | 2014-06-19 |
20140170082 | FLAVOR-IMPROVING METHOD - The present invention provides a novel method for improving the flavor of a food, drink, pharmaceutical product, oral care product, or the like. One aspect of the present invention is a method for improving the flavor of a food, drink, pharmaceutical product or oral care product, the method including the step of adding 0.1 to 10000 ppb of γ-aminobutyric acid and 0.01 to 10000 ppb of naringenin to the food, drink, pharmaceutical product, or oral care product. | 2014-06-19 |
20140170083 | ORALLY CONSUMABLE FORMULATIONS COMPRISING CERTAIN SWEET-TASTING TRITERPENES AND TRITERPENE GLYCOSIDES - The invention relates to triterpenes and triterpene glycosides of the formula (I) and/or physiologically acceptable salts thereof, preferably naturally occurring triterpenes and triterpene glycosides from | 2014-06-19 |
20140170084 | ORAL CARE COMPOSITION - The present invention relates to an oral care composition comprising catechins. We have found that the catechins tend to darken the colour of the chalk based toothpaste due to its oxidation which happens at the high pH of the toothpaste. Once the catechins are oxidized and darken the colour of the toothpaste it is no longer available as such for providing anti-inflammatory benefits. It is an object of the invention to provide a chalk based toothpaste formulation which does not turn substantially dark due to ox illation of catechins. The present inventors while working with oral care compositions comprising catechins preferably green tea catechins for providing anti-inflammatory benefits, surprisingly found that some selected zinc salts when added in particular quantities do not result in darkening the colour of the toothpaste, and also, when stored, are able to deliver green tea catechins. | 2014-06-19 |
20140170085 | COSMETIC PREPARATION TAILORED TO THE INDIVIDUAL USER AND PROCESS FOR PRODUCING SAME - A process for producing a cosmetic preparation wherein a cosmetic base, admixed with one or more cosmetic partial preparations or active ingredient concentrates, is mounted, in the package intended for the end user, in a dually asymmetric centrifuge, and is centrifuged in such a way that the cosmetic part preparations or active ingredient concentrates are distributed uniformly in the cosmetic base. | 2014-06-19 |
20140170086 | Method for Indicating Time for Washing or Indicating Delivery of Antibacterial Agent - A method for indicating release of an antibacterial agent or for indicating an amount of time for cleansing skin with an aqueous cleansing composition comprising a surfactant and a zinc X halide complex, wherein X is an amino acid or trimethylglycine, wherein the method comprises washing skin with the cleansing composition and water for a time until the zinc X halide complex precipitates from the aqueous cleansing composition. | 2014-06-19 |
20140170087 | UV-RESISTANT MICROBES AND UV-BLOCKING MICROBIAL EXTRACT - The present disclosure relates to a composition including an extract from an | 2014-06-19 |
20140170088 | BARIUM ZIRCONIUM OXIDE (BaZrO3.BaCO3) NANOPARTICLES - The present disclosure provides nanoparticles of barium zirconium oxide (BaZrO | 2014-06-19 |
20140170089 | PHOTOPROTECTIVE EYE CREAM AND METHODS - Photoprotectant cosmetic compositions adapted to application on a user's skin that include a sunscreen component comprising at least two sun-blocking components, each present in an amount sufficient to collectively provide ultraviolet A and B protection with an SPF of at least about 10; a mica component including mica in an amount sufficient to reduce or eliminate at least the appearance of dark skin adjacent an eye; and an oat peptide component in an amount sufficient to reduce or eliminate at least the appearance of fine lines and wrinkles on the user's skin. Methods of improving the aesthetic appearance of skin with such compositions are also included. | 2014-06-19 |
20140170090 | REDUCED-ALCOHOL SUNSCREEN COMPOSITIONS AND METHODS - Sunscreen compositions including a sunscreen component including avobenzone in an amount sufficient to provide at least UVA protection, an alcohol component present in a reduced-amount, and an antioxidant component present in an amount sufficient to impart an antioxidant effect to the sunscreen composition. In one aspect, the composition further includes a water-penetrating polymer in an amount sufficient to facilitate application of the composition in the presence of water. Methods of preparing and applying such reduced-alcohol compositions are also included. | 2014-06-19 |
20140170091 | Composition for Correcting Skin Pigment Conditions - The present invention relates to a composition that provides for skin pigment correction comprising: zinc oxide; octinoxate; α-arbutin; ascorbic acid; glycyrrhiza glabra extract; green tea extract; pomegranate extract; cucumber extract; niacinamide; and a carrier. The composition can be used to treat a variety of pigment issues including lentigo, liver spots, melasma, post-inflammatory pigment issues, sun spots, freckles, and age spots. | 2014-06-19 |
20140170092 | USE OF SPHINGANINE TO IMPROVE THE VISUAL APPEARANCE OF SKIN AND HAIR - The invention relates to the use of sphinganine for improving the visual appearance of skin and hair, for caring for, for protecting and/or for stimulating the growth of skin and hair. | 2014-06-19 |
20140170093 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 2014-06-19 |
20140170094 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 2014-06-19 |
20140170095 | SUNSCREEN COMPOSITIONS HAVING SYNERGISTIC COMBINATION OF UV FILTERS - The disclosure relates to sunscreen compositions having a synergistic combination of ultraviolet light (UV) filtering agents that provide a high sun protection factor (SPF). Compositions according to the disclosure have high SPF values without requiring high overall amounts of UV filtering agents. Furthermore, the disclosure relates to methods of using the described compositions for protecting keratinous substances such as skin and hair from UV radiation. | 2014-06-19 |
20140170096 | SUNSCREEN COMPOSITIONS - The present description refers to eco-compatible compositions for sunscreening the body, in particular to sunscreens for the protection of human health, compatible with organism life and not harmful to marine ecosystems (in particular for tropical environments with coral reefs). | 2014-06-19 |
20140170097 | Enhanced Substantivity of Cosmetic Ingredients on Keratinous Substrate - The invention provides compositions and methods for reversible covalent binding of benefit agents to keratinous substrates through the reaction of a dicarbonyl functional group on the surface of a benefit agent with reactive amines on keratinous surfaces. The deposits formed are durable and resistant to transfer, but are readily removed by contacting the deposit with an amine-containing solution. | 2014-06-19 |
20140170098 | NAIL VARNISH - The invention relates to a nail varnish having a viscosity of less than 50 mPas (Brookfield LV, DV III Ultra Rheometer, spindle: 40, RPM: 10, 25° C.) and a composition of: 20% to 85% by wt. of an aqueous polymeric dispersion as film former, with a solids fraction of 20% to 60%, 5% to 20% by wt. of a humectant, 1% to 10% by wt. of a colorant formed at least partly of a color pigment, 0.1% to 0.5% by wt. of a phyllosilicate, 0.5% to 5% by wt. of a surfactant, 0% to 5% by wt. of an additive, and remainder of water. | 2014-06-19 |
20140170099 | REMOVING TYPE AQUEOUS MANICURE COMPOSITION - Provided is a removing type aqueous manicure composition which is mild to nails while staying thereon and which can readily be removed by hot water and commercial soaps without using removers containing acetone and acetate esters, so that it can meet a volatile organic compound (VOC) emission control. | 2014-06-19 |
20140170100 | OXIDATIVE HAIR TREATMENT WITH SILICONE AND BLEACH - The subject matter of the present invention is a method for oxidative lightening and/or coloring of keratinic fibers, in particular of hair, wherein
| 2014-06-19 |
20140170101 | Antiperspirant and Deodorant Compositions - The present application relates to antiperspirant compositions comprising nitrogen-based and/or oxygen based perfume raw materials, and methods for making and using the antiperspirant compositions. | 2014-06-19 |
20140170102 | Antiperspirant and Deodorant Compositions - The present application relates to antiperspirant compositions comprising perfumes and sulfur-based perfume raw materials, and methods for making and using the antiperspirant compositions. | 2014-06-19 |
20140170103 | Conditioning Agents for Personal Care Compositions - An emollient represented by the formula: | 2014-06-19 |
20140170104 | HAIR TREATMENT COMPOSITIONS - The present invention relates to hair treatment compositions and methods. More particularly, the invention relates to hair treatment compositions comprising lipids and creatine. The hair treatment compositions of the present invention may be used to improve the tensile properties of hair, such as hair elasticity and strength. | 2014-06-19 |
20140170105 | COSMETIC COMPOSITIONS CONTAINING AN ALKOXYSILANE AND A SILSESQUIOXANE RESIN - The present invention relates to composition for styling hair comprising: (a) a first phase comprising: at least one alkoxysilane having at least one solubilizing functional group and at least one amino substituent; at least one water-soluble metal salt; at least one acidifying agent; and at least one cosmetically acceptable carrier comprising water; and (b) a second phase comprising: at least one silsesquioxane resin and at least one volatile solvent. The present invention also relates to methods of styling hair. | 2014-06-19 |
20140170106 | METHODS AND COMPOSITIONS SUITABLE FOR IMPROVED REATTACHMENT OF DETACHED CARTILAGE TO SUBCHONDRAL BONE - The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage. | 2014-06-19 |
20140170107 | REGULATION OF ENERGY METABOLISM AND OBESITY BY MODULATING B CELL ACTIVATING FACTOR (BAFF, BLYS) OR BAFF SIGNALING - Provided herein are methods and compositions for modulating energy metabolism and weight in mammals, in particular by modulating thermogenesis associated with brown fat, including thermogenesis by brown fat or brown fat cells, adaptive thermogenesis by brown fat or brown fat cells, thermogenic capacity of brown fat or brown fat cells, or a combination thereof. More specifically, methods and compositions provided herein for treating or preventing obesity, or methods and compositions for identifying compounds effective for treating or preventing obesity are taught in connection with ligands such as B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), their receptors, and molecules that modulate the interactions between the ligands and receptors. | 2014-06-19 |
20140170108 | COMPOSITIONS USEFUL FOR THE TREATMENT OF INFLAMMATORY DISEASE OR DISORDERS - The present invention provides sustained release and long acting forms of peptide therapeutic, particularly Interleukin-1 receptor antagonist (IL-1ra), including multimeric forms of IL-1ra, including variants of IL-1ra which are capable of multimerising, and compositions comprising the long acting and multimeric forms of IL-1ra, and a process of preparation thereof. The present invention also provides compositions comprising the multimeric forms of IL-1ra, including IL-1raK, KIL-1ra and KIL-1raK, which are effective in inhibiting, treating and/or ameliorating rheumatoid disease, inflammatory diseases or disorders, autoinflammatory disorders or conditions resulting from adverse effects of Interleukin-1 (IL-1). Methods of treating a subject comprising administering the composition comprising the multimeric forms of IL-1ra are also provided. | 2014-06-19 |
20140170109 | IL-12 IMMUNOCONJUGATE - Conjugate comprising interleukin-12 (IL-12) and a single chain targeting portion comprising two antigen binding sites. The targeting portion may comprise an antibody fragment such as a single chain diabody. The conjugate may be a single chain fusion protein. Use of single chain bivalent IL-12 immunocytokine for targeting the extra-cellular matrix (ECM) of tissues, particularly tumour neovasculature antigens, for example fibronectin. Use for treating cancer or pathological angiogenesis in a patient. | 2014-06-19 |
20140170110 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES - Compounds having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK). | 2014-06-19 |
20140170111 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES - The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A′, B, G, R | 2014-06-19 |
20140170112 | COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM - In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation. | 2014-06-19 |
20140170113 | Methods for treating and/or limiting development of diabetes - The present invention provides methods for identifying candidate compounds for limiting development of and/or treating diabetes, and methods for limiting development of and/or treating diabetes. | 2014-06-19 |
20140170114 | GLYPICAN-3-SPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. | 2014-06-19 |
20140170115 | Enzyme and Prebiotic Combinations for Enhancing Probiotic Growth and Efficacy - This disclosure relates to enhancing growth and/or activity of lactobacilli using a prebiotic formulation which includes iso-malto oligosaccharides and α-galactosidase; and to enhancing growth and/or activity of bifidobacteria using a prebiotic formulation which includes iso-malto oligosaccharides and β-glucanase. Other combinations of fibers and enzymes are described below which also stimulate growth and activity of lactobacilli or bifidobacteria. These combinations of enzymes and prebiotics can be taken separately or added to foods, including desserts. | 2014-06-19 |
20140170116 | METHOD OF TREATING ISCHEMIC DISORDERS - A method of treating an ischemic disorders in a subject includes administering stromal cell derived factor-1 (SDF-1) to ischemic tissue of the subject in an amount effective to inhibit apoptosis of cells of the tissue. | 2014-06-19 |
20140170117 | Fabrication Of Bone Regeneration Scaffolds And Bone Filler Material Using A Perfusion Flow System - The present disclosure is directed at a process to form bone grafting material. One may provide a porous collagen scaffold and insert the scaffold into a perfusion chamber of a perfusion flow system. This may then be followed by continuously providing a mineralization perfusion fluid flow through the scaffold at a flow rate to provide dynamic intrafibrillar mineralization of the scaffold and form a collagen/hydroxyapatite composite scaffold. One may optionally provide the scaffold with bone tissue forming cells and then deliver a perfusion fluid including oxygen and one or more nutrients through the collagen/hydroxyapatite composite scaffold and to the bone tissue forming cells at a flow rate such that the bone tissue forming cells remodel the collagen/hydroxyapatite composite scaffold and form a bone tissue extracellular matrix. The bone tissue extracellular matrix may then be decellularized to form an acellular bone repair scaffold. | 2014-06-19 |
20140170118 | METHODS OF DIFFERENTIATING STEM CELLS BY MODULATING MIR-124 - Provided herein are methods of differentiating stem cells via modulating miR-124, and the differentiated cells thereby. Also provided herein are methods for the treatment of diseases using the differentiated cells. | 2014-06-19 |
20140170119 | MULTI-CHAMBER APPLICATOR FOR GELATIN SOLUTION - Disclosed is a multi-chamber applicator comprising an aqueous gelatin solution and an aqueous cross-linking agent solution in separate chambers. | 2014-06-19 |
20140170120 | CYTOKINE INDUCTION OF SELECTIN LIGANDS ON CELLS - Methods and compositions for treating cells with cytokines are provided herein. | 2014-06-19 |
20140170121 | Neural Scaffolds - Disclosed herein are compositions and methods useful for preparing neural scaffolds. The scaffolds comprise tissue taken from the spinal cord and/or dura mater of vertebrate and can be processed to form gels or sheets. Methods of treating patient with CNS injury are also presented. | 2014-06-19 |
20140170122 | ADULT STEM CELLS DERIVED FROM HUMAN SKIN DERMIS - Provided in the present invention are adult stem cells derived from human skin dermis, and a method for isolating same. Further provided in the present invention are osteoblastic cells and adipocytes differentiated from the adult stem cells derived from human skin dermis, and a differentiation method therefor. Further provided in the present invention is a composition for osteogenesis or lipogenesis containing the stem cells, osteoblastic cells, or adipocytes. The isolation method of the present invention enables the adult stem cells derived from human skin dermis to be obtained in an easy and simple manner at a high yield rate. Genes and growth factors which are specifically expressed in the adult stem cells derived from human skin dermis isolated using the method can be separated, identified, and used later. | 2014-06-19 |
20140170123 | Hepatocyte Based Insulin Gene Therapy For Diabetes - A method and vectors for controlling blood glucose levels in a mammal are disclosed. In one embodiment, the method comprises the steps of: treating the hepatocyte cells of a patient with a first, second or third vector, wherein the first vector comprises a promoter enhancer, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase and an albumin 3′UTR and lacks an HGH intron, wherein the second vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site and an albumin 3′UTR and lacks a promoter enhancer, wherein the third vector comprises an HGH intron, glucose inducible regulatory elements, a liver-specific promoter, a gene encoding human insulin with modified peptidase site, an albumin 3′UTR and a promoter enhancer and observing the patient's insulin levels, wherein the patient's insulin levels are controlled. | 2014-06-19 |
20140170124 | METHODS AND USES OF A MODIFIED CECROPIN FOR TREATING ENDOPARASITIC AND BACTERIAL INFECTIONS - The present disclosure provides a modified cecropin protein comprising a cecropin or a variant thereof fused to a hydrophilic tail lacking a C-terminal glycine. The present disclosure also provides pharmaceutical compositions, methods and uses of the modified cecropin protein or nucleic acid for treating or preventing endoparasites, such as | 2014-06-19 |
20140170125 | USE OF CARDIOTROPHIN-1 FOR THE TREATMENT OF KIDNEY DISEASES - The present invention relates to the use of cardiotrophin-1 (CT-1) for the prevention and/or treatment of acute renal injury, specially of acute kidney injury induced by nephrotoxic agents, such as contrast agents, antibiotics, immunosuppressive agents or antineoplastic agents. The invention is also related to compositions comprising said nephrotoxic agents and cardiotrophin-1. | 2014-06-19 |
20140170126 | PROBIOTIC FOR ADMINISTRATION TO HEALTHY YOUNG MAMMALS DURING THE WEANING PERIOD FOR IMPROVING TOLERANCE TO NEWLY INTRODUCED FOOD STUFFS - The current invention is based upon administration of a probiotic, | 2014-06-19 |
20140170127 | INOSITOL PYROPHOSPHATES, AND METHODS OF USE THEREOF - The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphospahte (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to deliver oxygen, by delivering IHP to the cytoplasm of the red blood cells. | 2014-06-19 |
20140170128 | COMPOSITIONS FOR THE MANAGEMENT OF GLYCATED HEMOGLOBIN AND BLOOD GLUCOSE - Disclosed herein are compositions, products, and methods that treat glycated hemoglobin- and blood glucose-affected conditions by improving insulin function for the control and maintenance of blood glucose levels, alleviating oxidative stress, minimizing the risk of developing disease complications, facilitating the loss of weight and maintenance of healthy weight, and at the same time fulfill cravings for pleasant-tasting items of consumption and in turn increase the likelihood of patient compliance with the relevant therapy regimen. The disclosed compositions, products, and methods implement proteins and peptides that provide insulinotropic metabolic products in a sustained manner, in combination with ingredients that, for example, provide sustained release of carbohydrates, steady energy, sustained antioxidant effect relieve oxidative stress, and promote satiety, in order to reduce A1c and blood glucose levels and avert weight gain among subjects in need. | 2014-06-19 |
20140170129 | PREPARATION OF STABILIZED CATALASE ENZYMES WITH A SURFACTANT - There is provided a method of producing a stabilized microcrystalline cellulose powder containing catalase enzyme. In the method, cellulose is thoroughly mixed with phosphate borate and catalase, rinsed with water and a surfactant added. The stabilized powder may be mixed with various skin solutions (lotions, ointments and the like). The catalase enzyme can catalyze the reaction of peroxide to oxygen. | 2014-06-19 |
20140170130 | STEP-Derived Peptide for Brain Injury Treatment - A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder. | 2014-06-19 |
20140170131 | Compositions and Methods for the Treatment and Prevention of Infections Caused by Staphylococcus aureus Bacteria - The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of | 2014-06-19 |
20140170132 | PROPHYLATIC TREATMENT OF HERPES RECURRENCE - The present invention relates to methods for prophylactic treatment of Herpes recurrence with a Clostridial neurotoxin, such as a | 2014-06-19 |
20140170133 | ALTERATION OF PROTEOLYTIC CLEAVAGE OF BOTULINUM NEUROTOXINS - The present invention pertains to a polynucleotide encoding a modified neurotoxin polypeptide comprising a modified neurotoxin light chain and a heavy chain, said modified light chain having at least one modification conferring altered cleavage by calpain proteases. Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the said polynucleotide. In addition, the invention relates to compositions comprising the polynucleotide, vector, host cell or polypeptide of the invention as a medicament. | 2014-06-19 |
20140170134 | COMPOSITIONS AND METHODS RELATED TO ANTIBODIES TO STAPHYLOCOCCAL PROTEIN A - Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2014-06-19 |
20140170135 | EGFR EXPRESSION IS ASSOCIATED WITH DECREASED BENEFIT FROM TRASTUZUMAB IN THE NCCTG N9831 TRIAL - The subject invention provides a method for treating a patient having a tumor associated with HER2+ breast cancer comprising: measuring in a sample of the patient's tumor a level of expression of epidermal growth factor receptor protein by using an antibody that detects the cytoplasmic domain of epidermal growth factor receptor; and comparing the level of expression of epidermal growth factor receptor protein in the patient's tumor so measured with a reference value; wherein if the level of expression of epidermal growth factor receptor measured is higher than the reference value, treating the patient with a therapy other than trastuzumab. | 2014-06-19 |
20140170136 | ANTI-NERVE GROWTH FACTOR ANTIBODIES AND METHODS OF PREPARING AND USING THE SAME - A method of preparing an antibody suitable for use in an equine is provided. Also provided are equinised antibodies which specifically bind to equine neuronal growth factor (NGF) and neutralise the ability of equine NGF to bind to the p75 or TrkA equine NGF receptor. The invention extends to nucleic acids encoding same and to methods of treating pain and arthritis in an equine using said antibodies and/or nucleic acids. | 2014-06-19 |
20140170137 | THERAPEUTIC CANINE IMMUNOGLOBULINS AND METHODS OF USING SAME - A method of preparing a canine antibody suitable for use in the therapeutic treatment of a canine is provided. In particular, there is provided immunoglobulins which can be selected for the characteristic of whether they mediate downstream complement mediated immune activation when bound to a target antigen. Canine derived antibodies comprising specific heavy chain isotypes are provided. The invention extends to the use of the immunoglobulins of the invention in methods of treating conditions such as pain, inflammatory conditions and cancerous conditions in a canine. | 2014-06-19 |
20140170138 | HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6, METHODS AND USES THEREOF - The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by SEQ ID NO. 15, that is an HSP65 derived peptide. More specifically, the invention relates to humanized anti-peptide-6 antibodies, compositions, methods and uses thereof for the treatment of immune-related disorders, specifically, inflammatory disorders such as arthritis, IBD, psoriasis, diabetes and MS. The invention further provides combined compositions and kit combining the humanized antibodies of the invention and at least one anti-inflammatory agent, as well as uses of the humanized antibodies in diagnostic kits and methods. | 2014-06-19 |
20140170139 | HYPOXIA-RELATED GENE SIGNATURES FOR CANCER CLASSIFICATION - Biomarkers, particularly hypoxia-related genes, and methods using the biomarkers for molecular detection and classification of disease are provided. | 2014-06-19 |
20140170140 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROMYELITIS OPTICA - The present invention is directed to antibodies binding to aquaporin 4 (AQP4) and methods of using such antibodies to treat neuromyelitis optica (NMO) either as a monotherapy or in combination with standard NMO therapies such as immunosuppressives or plasmaphersis. | 2014-06-19 |
20140170141 | POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION - This invention relates to C1ORF32 protein and its variants and fragments and fusion proteins thereof, pharmaceutical composition comprising same and methods of use thereof for treatment of immune related disorders and infections. | 2014-06-19 |
20140170142 | Molecules With Extended Half-Lives And Uses Thereof - The invention is directed to a molecule comprising an albumin binding domain (ABD) and an FcRn binding moiety, wherein said molecule has enhanced pharmacologic properties in vivo. | 2014-06-19 |
20140170143 | USE OF AN ANTI-CD200 ANTIBODY FOR PROLONGING THE SURVIVAL OF ALLOGRAFTS - The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein. | 2014-06-19 |
20140170144 | ANTIBODY RECOGNIZING N-DOMAIN OF MIDKINE - The present disclosure relates to isolated or recombinant proteins, such as antibodies, which inhibit or reduce the function of midkine (hereinafter, referred to as “MK”) for use in the treatment or prevention of midkine-related disorders. | 2014-06-19 |
20140170145 | COMPOSITIONS AND METHODS OF USE FOR MGD-CSF IN DISEASE TREATMENT - Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss. | 2014-06-19 |
20140170146 | METHODS FOR MULTIPLEXED DRUG EVALUATION - Methods for multiplexed delivery of agents to a solid tissue in vivo followed by assessment of efficacy with mass spectrometry are described. | 2014-06-19 |
20140170147 | COMPOSITIONS AND METHODS OF USE FOR ANTIBODIES OF DICKKOPF-1 - Antibodies and fragments that bind to the protein target Dickkopf (DKK1) are provided, as are methods of use and kits, for treating a target cell, in particular, a cell associated with an osteolytic condition. | 2014-06-19 |
20140170148 | BISPECIFIC ANTIBODIES AGAINST HER2 - Bispecific antibodies which comprise antigen-binding regions binding to two different epitopes of human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods of preparing and using the antibodies are also disclosed. | 2014-06-19 |
20140170149 | BISPECIFIC ANTIBODIES AGAINST HER2 AND CD3 - Bispecific antibodies which comprise one antigen-binding region binding to an epitope of human epidermal growth factor receptor 2 (HER2) and one antigen-binding region binding to human CD3, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and methods for preparing and using the antibodies are also disclosed. | 2014-06-19 |
20140170150 | N-LINKED GLYCAN COMPOUNDS - An isolated or purified compound is provided, comprising A-GlcNAc[GlcNAc]-GalNAc-GalNAc-QuiNAc4NAc, wherein A is GlcNAc or Glc. There is further provided a vaccine based on such compound, having particular use to treat or prevent an infection caused by a | 2014-06-19 |
20140170151 | Synthetic Oligosaccharides for Staphylococcus Vaccine - The present invention synthetic oligo-β-(1→6)-glucosamine structures and a methodology which essentially allows for the synthesis of any oligo-β-(1→6)-glucosamine species having a definite number of monosaccharide units, including a set pattern of acetylated and non-acetylated residues. The invention further provides antibodies to these synthetic oligo-β-(1→6)-glucosamines as well as compositions thereof and methods for treating and preventing infections caused by bacteria expressing poly-β-(1→6)-glucosamines, such as | 2014-06-19 |
20140170152 | IMMUNOBINDERS DIRECTED AGAINST TNF - Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-α), e.g., human TNF-α, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies. | 2014-06-19 |
20140170153 | IL-21 EPITOPE AND IL-21 LIGANDS - The present invention relates to IL-21 ligands, such as e.g. antibodies, as well as use thereof. | 2014-06-19 |
20140170154 | ENGINEERED ANTI-IL-23R ANTIBODIES - Antibodies to human IL-23R are provided, as well as uses thereof, e.g. in treatment of inflammatory, autoimmune, and proliferative disorders. | 2014-06-19 |